Peptidomimetics in cancer targeting
Open Access
- 7 December 2022
- journal article
- review article
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-17
Abstract
The low efficiency of treatment strategies is one of the main obstacles to developing cancer inhibitors. Up to now, various classes of therapeutics have been developed to inhibit cancer progression. Peptides due to their small size and easy production compared to proteins are highly regarded in designing cancer vaccines and oncogenic pathway inhibitors. Although peptides seem to be a suitable therapeutic option, their short lifespan, instability, and low binding affinity for their target have not been widely applicable against malignant tumors. Given the peptides’ disadvantages, a new class of agents called peptidomimetic has been introduced. With advances in physical chemistry and biochemistry, as well as increased knowledge about biomolecule structures, it is now possible to chemically modify peptides to develop efficient peptidomimetics. In recent years, numerous studies have been performed to the evaluation of the effectiveness of peptidomimetics in inhibiting metastasis, angiogenesis, and cancerous cell growth. Here, we offer a comprehensive review of designed peptidomimetics to diagnose and treat cancer.Keywords
This publication has 143 references indexed in Scilit:
- An Antimicrobial Peptidomimetic Induces Mucorales Cell Death through Mitochondria-Mediated ApoptosisPLOS ONE, 2013
- The Multi-Leu Peptide Inhibitor Discriminates Between PACE4 and Furin And Exhibits Antiproliferative Effects On Prostate Cancer CellsJournal of Medicinal Chemistry, 2012
- Structural and Dynamic Determinants of Protein-Peptide RecognitionStructure, 2011
- Using Modularly Assembled Ligands To Bind RNA Internal Loops Separated by Different DistancesChemBioChem, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 ProteinJournal of Biomolecular Structure and Dynamics, 2010
- Identification and Rational Redesign of Peptide Ligands to CRIP1, A Novel Biomarker for CancersPLOS Computational Biology, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007
- The Hallmarks of CancerCell, 2000